On August 1, 2023, PENUMBRA ($NYSE:PEN) released their financial results for the second quarter of FY2023, which ended on June 30, 2023. Compared to the same quarter in the previous year, total revenue increased by 25.5% to USD 261.5 million and net income rose to USD 19.0 million, a significant improvement from the negative USD 3.7 million reported a year earlier.
On Tuesday, PENUMBRA Inc. reported their second quarter earnings results for the period ending June 30th, 2023. Stock opened at $300.0 on Tuesday and closed at $298.3, representing a decrease of 1.7% from the previous day’s closing price of 303.4. This resulted in lower bottom-line profits than expected, causing the stock to take a hit.
Despite the stock dip, PENUMBRA’s management is confident in the company’s long-term prospects and is committed to continue executing on their growth strategy. They remain optimistic about their future financial performance and believe that their current strategies will help them to achieve their goals in the coming quarters. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Penumbra. PENUMBRA_Reports_Q2_Earnings_Results_for_Period_Ending_June_30_2023″>More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Penumbra. PENUMBRA_Reports_Q2_Earnings_Results_for_Period_Ending_June_30_2023″>More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Penumbra. PENUMBRA_Reports_Q2_Earnings_Results_for_Period_Ending_June_30_2023″>More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Penumbra are shown below. PENUMBRA_Reports_Q2_Earnings_Results_for_Period_Ending_June_30_2023″>More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
At GoodWhale, we take a close look at PENUMBRA’s financials to provide our clients with risk ratings. After thorough analysis, we have determined that PENUMBRA is a high risk investment, both in terms of financial and business aspects. Our team has identified two potential risk warnings in the balance sheet – non financial – and we invite you to register with us to view the findings. With our detailed research and comprehensive recommendations, we can help you make the most informed decision about your investments. More…
Risk Rating Analysis
Star Chart Analysis
The medical device industry is extremely competitive, with Penumbra Inc competing against well-established companies such as LifeTech Scientific Corp, NuVasive Inc, and Tandem Diabetes Care Inc. While each company has its own strengths and weaknesses, Penumbra Inc has been able to stay ahead of the competition by offering innovative products and services that cater to the needs of their customers.
– LifeTech Scientific Corp ($SEHK:01302)
LifeTech Scientific Corp is a leading provider of scientific and medical products. The company has a market cap of 13.29B as of 2022 and a return on equity of 8.24%. LifeTech Scientific Corp manufactures and sells a wide range of products, including medical devices, laboratory equipment, and pharmaceuticals. The company has a strong focus on research and development, and its products are used by scientists and medical professionals around the world.
NuVasive Inc is a medical device company that develops minimally-invasive products and procedures for treating spine disorders. The company has a market capitalization of $2.17 billion and a return on equity of -1.33%. NuVasive’s products are used by spine surgeons to treat conditions such as degenerative disc disease, scoliosis, and spinal tumors. The company’s minimally-invasive procedures enable patients to recover more quickly and experience less pain than with traditional open surgery.
– Tandem Diabetes Care Inc ($NASDAQ:TNDM)
Tandem Diabetes Care Inc is a medical device company that manufactures and sells insulin pumps for people with diabetes. The company has a market cap of 3.48B as of 2022 and a Return on Equity of -1.09%. Tandem Diabetes Care Inc was founded in 2006 and is headquartered in San Diego, California.
PENUMBRA released their Q2 2023 financials on August 1 2023, showing impressive year-over-year growth. Total revenue was USD 261.5 million, a 25.5% increase from the same quarter in the prior year. Net income was USD 19.0 million, a notable turnaround from the -3.7 million posted in the same quarter of the previous year.
This strong performance reflects PENUMBRA’s successful strategies, indicating potential for continued growth. Investors should monitor their future results to evaluate further investment opportunities.